Shares of Pasithea Therapeutics Corp. (NASDAQ:KTTA – Get Free Report) fell 3.4% during trading on Friday . The stock traded as low as $0.75 and last traded at $0.75. 299,809 shares changed hands during trading, a decline of 86% from the average session volume of 2,073,040 shares. The stock had previously closed at $0.77.
Pasithea Therapeutics Stock Down 3.4%
The company has a market cap of $5.57 million, a price-to-earnings ratio of -0.07 and a beta of 0.33. The company’s 50-day moving average is $1.10 and its 200 day moving average is $1.66.
Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($1.61) EPS for the quarter.
About Pasithea Therapeutics
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.
Read More
- Five stocks we like better than Pasithea Therapeutics
- The Significance of Brokerage Rankings in Stock Selection
- New All-Time Highs Coming for Broadcom? Wall Street Says Yes
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Overheated Market? Analysts Watch These Red Flags
- Stock Market Upgrades: What Are They?
- 3 Reasons AMD Could Be the Hottest Stock of the Summer
Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
